BamSEC and AlphaSense Join Forces
Learn More

Isoray.

NYSE American: CATX    
Share price (11/21/24): $3.00    
Market cap (11/21/24): $203 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 18 pages Re: Terms of Separation Dear Mark: This Letter Confirms the Agreement (“Agreement”) Between You and Perspective Therapeutics, Inc. (The “Company”) Concerning the Terms of Your Separation and Offers You the Separation Compensation We Discussed in Exchange for a General Release of Claims and Covenant Not to Sue. 1
12/34/56
EX-10.2
from 8-K 11 pages Certain Confidential Information Contained in This Document, Marked by “[***]”, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Statement of Work No. 1 Pursuant to Master Equipment and Services Agreement
12/34/56
EX-10.1
from 8-K 30 pages Certain Confidential Information Contained in This Document, Marked by “[***]”, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Master Equipment and Services Agreement
12/34/56
EX-10.2
from 10-Q 17 pages Isoray, Inc. 2017 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 23 pages General Purpose. the Name of This Plan Is the Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan (The “Plan”). the Purposes of the Plan Are to (A) Enable Perspective Therapeutics, Inc., a Delaware Corporation (The “Company”), and Any Affiliate to Attract and Retain the Types of Employees, Consultants and Directors Who Will Contribute to the Company’s Long Range Success; (B) Provide Incentives That Align the Interests of Employees, Consultants and Directors With Those of the Stockholders of the Company; and (C) Promote the Success of the Company’s Business. 1.2
12/34/56
EX-10.1
from 8-K 17 pages Annex B Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan
12/34/56
EX-10.28
from 10-K 13 pages Mayo Foundation for Medical Education and Research Patent License Agreement
12/34/56
EX-10.26
from 10-K 20 pages Registration Rights Agreement
12/34/56
EX-10.6
from 10-K 9 pages Form of Indemnification Agreement
12/34/56
EX-10.3
from 8-K 21 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 16 pages Placement Agency Agreement
12/34/56
EX-10.1
from 8-K 31 pages Investment Agreement
12/34/56
EX-10.3
from 8-K/A 21 pages Option Agreement
12/34/56
EX-10.2
from 8-K/A 38 pages Asset Purchase Agreement by and Between Progenics Pharmaceuticals, Inc., as Seller, Perspective Therapeutics, Inc., as Purchaser, and for Purposes of Section 9.12 Only Lantheus Medical Imaging, Inc. as Guarantor Dated as of January 8, 2024
12/34/56
EX-10.1
from 8-K/A 30 pages Investment Agreement
12/34/56
EX-10.1
from 8-K 19 pages Certain Confidential Information Contained in This Document, Marked by “[**]”, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.1
from 10-Q 9 pages Confidential Separation Agreement and General Release
12/34/56
EX-10.1
from 8-K 22 pages Perspective Therapeutics, Inc. Second Amended and Restated 2020 Equity Incentive Plan
12/34/56
EX-10.3
from 8-K 17 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 17 pages Employment Agreement
12/34/56